88,855 Shares in Harrow, Inc. $HROW Bought by Lumbard & Kellner LLC

Lumbard & Kellner LLC acquired a new position in Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 88,855 shares of the company’s stock, valued at approximately $4,281,000. Harrow comprises about 1.6% of Lumbard & Kellner LLC’s investment portfolio, making the stock its 26th largest position. Lumbard & Kellner LLC owned about 0.24% of Harrow as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Blackhawk Capital Partners LLC purchased a new position in Harrow in the third quarter valued at about $5,272,000. Divisadero Street Capital Management LP purchased a new stake in shares of Harrow during the 2nd quarter worth approximately $4,293,000. Brookstone Capital Management raised its holdings in shares of Harrow by 232.5% in the 3rd quarter. Brookstone Capital Management now owns 45,775 shares of the company’s stock worth $2,205,000 after purchasing an additional 32,009 shares during the period. Geode Capital Management LLC raised its holdings in shares of Harrow by 4.7% in the 2nd quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock worth $24,765,000 after purchasing an additional 36,724 shares during the period. Finally, Calamos Advisors LLC purchased a new position in Harrow in the third quarter valued at approximately $1,088,000. Institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $94.00 target price on shares of Harrow in a research report on Tuesday, November 11th. Zacks Research downgraded Harrow from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. LADENBURG THALM/SH SH boosted their price objective on Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Finally, HC Wainwright increased their target price on shares of Harrow from $64.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Harrow has an average rating of “Moderate Buy” and an average target price of $71.43.

Harrow Stock Performance

NASDAQ:HROW opened at $54.18 on Monday. The business’s fifty day moving average is $48.53 and its 200 day moving average is $43.70. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -541.75 and a beta of 0.05. The company has a debt-to-equity ratio of 5.21, a quick ratio of 2.52 and a current ratio of 2.72. Harrow, Inc. has a 52-week low of $20.85 and a 52-week high of $54.85.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.